Now showing items 1-10 of 14
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity
(Springer-Verlag, 1987-02)
We compared the acute tubular nephrotoxicity of three platinum compounds in children and adults with solid tumors by monitoring the urinary excretion of alanine aminopeptidase, N -acetyl-β-D-glucosaminidase, and total ...
Phase II trial of N-methylformamide in advanced head and neck cancer
(Kluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Media, 1987-06)
Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M 2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior ...
High-dose cisplatin in advanced head and neck cancer
(Springer-Verlag, 1987-04)
In 22 patients with advanced squamous cell carcinoma of the head and neck we evaluated the efficacy and toxicity of 200 mg/m 2 cisplatin administered in 3% NaCl with vigorous hydration. Six patients had previously untreated ...
A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck
(Kluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Media, 1985-12)
Sixteen patients with advanced squamous cell carcinoma of the head and neck were entered into a phase II trial of Aclacinomycin-A (ACM), 100 mg/M 2 administered by brief infusion every three weeks. All patients had received ...
Cisplatin, VP-16-213 and MGBG (Methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study
(Kluwer Academic Publishers; Springer Science+Business Media, 1988-09)
In an effort to improve the treatment of patients with refractory or recurrent lymphoma, we developed a protocol using cis-platinum combined with two other agents of known efficacy in these disorders but with differing ...
Phase II evaluation of MGBG in non-small cell carcinoma of the lung
(Martinus Nijhoff, The Hague/Kluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Media, 1983-03)
One hundred and eight patients with non-small cell lung cancer were treated in a Phase II trial with MGBG at a dose of 600 mg/m 2 i.v. weekly. Partial responses were noted in 3/43 patients with adenocarcinoma and 1/40 with ...
Hepatic arterial chemotherapy for primary and metastatic liver cancers
(Springer-Verlag, 1989-01)
Hepatic arterial chemotherapy represents a means of selectively exposing hepatic tumor to cytotoxic agents. Although 5-fluoro-2′-deoxyuridine has been shown to generate a higher response rate in the treatment of colorectal ...
Response of human HT-29 colorectal tumor cells to extended exposure to bromodeoxyuridine
(Springer-Verlag, 1989-01)
Effects of the extended exposure of a human colorectal tumor-cell line (HT-29) to bromodeoxyuridine (BrdUrd) were studied in anticipation of the clinical use of that agent to treat colorectal cancer, particularly as a ...
Pharmacologic studies on the dibutyl and γ-monobutyl esters of methotrexate in the rhesus monkey
(Springer-Verlag, 1982-12)
The pharmacokinetics and metabolism of dibutyl methotrexate (DBMTX) and γ-monobutyl methotrexate (γ-MBMTX) were studied in Rhesus monkeys. When a bolus IV dose of either [ 3 H]DBMTX or [ 3 H]γ-MBMTX was given, the principal ...
Prediction of thioguanine-induced cytotoxicity by dual-parameter flow cytometric analysis
(Springer-Verlag, 1989-10)
A method is presented for the quantitative analysis of delayed cytokinetic effects resulting from the treatment of L1210 cells with 6-thioguanine (TG). By using dual-parameter (DNA/protein) flow cytometry, we could observe ...